# How a Specific Peptide Boosts the Immune System Against Cancer > This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy. - **Patent:** US 11542303 - **Original title:** Peptides and combination thereof for use in the immunotherapy against cancers - **Owner:** Immatics Biotechnologies - **Granted:** 2023 - **Status:** Active - **Times cited:** 1 - **Field:** biotech, pharmaceutical, immunotherapy ## What it does This patent claims a specific recipe for a cancer treatment. It involves a particular protein fragment, called a peptide, with the exact amino acid sequence KESDGFHRF (Claim 1). This peptide is combined with an 'adjuvant,' which is a substance that helps make the immune response stronger. The patent lists several possible adjuvants, including imiquimod, GM-CSF, and various interleukins like IL-2, IL-7, IL-12, IL-15, and IL-21 (Claim 2). All these ingredients are mixed into a 'pharmaceutically acceptable carrier,' which is a safe way to deliver the medicine to a patient. For example, a composition could include the KESDGFHRF peptide, IL-2 as the adjuvant (Claim 3), and a buffer for stability (Claim 8), all within a safe liquid carrier for injection. ## What it does NOT cover - Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF. - Does not cover the peptide KESDGFHRF when administered without an adjuvant. - Does not cover the peptide KESDGFHRF without a pharmaceutically acceptable carrier. - Does not cover using only the listed adjuvants without the specific KESDGFHRF peptide. - Does not cover non-immunotherapy treatments for cancer, such as chemotherapy alone. ## The clever bit The novelty lies in identifying and claiming a very specific nine-amino-acid peptide, KESDGFHRF, as a key component for stimulating an immune response against tumors. The patent then combines this specific peptide with known immune-boosting adjuvants and delivery methods, creating a precise formulation for immunotherapy. ## Real-world examples 1. Experimental cancer vaccines 2. T-cell stimulating therapies 3. Immunotherapy drug candidates ## Why it matters Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers. ## Frequently asked questions ### What does How a Specific Peptide Boosts the Immune System Against Cancer cover? This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy. ### Who owns patent US 11542303? Immatics Biotechnologies owns this patent, granted in 2023. ### When does this patent expire? This patent is expected to expire on June 25, 2041, when the invention enters the public domain. ### What is patent US 11542303 cited by? This patent has been cited by 1 later patents that build on its ideas. ### What problem does this patent solve? Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers. ### What does this patent NOT cover? Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF. **Full plain-English explainer:** https://patentbrief.org/patent/us/11542303/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers **Original patent:** https://patents.google.com/patent/US11542303 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer](https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca) — This patent describes methods to fight various cancers by using a specific protein fragment (peptide LYHDIFSRL) to train a patient's immune cells to recognize and attack tumor cells. - [Using Specific Immune Cells to Fight Cancers Like Lung and Breast Cancer](https://patentbrief.org/patent/us/11407807/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-tu) — This patent describes a method to treat specific cancers, including lung, breast, and ovarian cancer, by giving patients their own immune cells (T cells) that have been trained to recognize and destroy cancer cells presenting a unique protein fragment. - [Training Immune Cells to Fight Specific Cancers](https://patentbrief.org/patent/us/10364282/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-esophageal) — This patent describes a method to treat specific cancers like esophageal or lung cancer by creating specialized immune cells in the lab and giving them to patients to kill cancer cells that display a particular protein fragment. - [Targeting Liver and Bile Duct Cancers with Specific Immune Cells](https://patentbrief.org/patent/us/11560405/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers-11560405) — This patent describes a method to treat liver and bile duct cancers by using specially activated immune cells that recognize a unique protein fragment found on these cancer cells. - [Training Immune Cells to Fight Cancer Using Specific Markers](https://patentbrief.org/patent/us/10377797/cell-epitopes-and-combination-of-cell-epitopes-for-use-in-the-immunotherapy-of-m) — This patent describes a method to create a powerful immune response against cancer by taking a patient's own T cells, teaching them to recognize specific cancer markers outside the body, and then putting them back to kill cancer cells.